Life Science News

ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Bristol-Myers Squibb Company Class: Investors who received Contingent Value Rights in exchange for their shares of Celgene Corporation pursuant to Bristol-Myers’ acquisition of Celgene on November 20, 2019 Lead Plaintiff Motion Deadline: December 6, 2021 MISLEADING ...

ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://claimsfiler.com/cases/nyse-bmy-3/

Owlet, Inc. f/k/a Sandbridge Acquisition Corporation (OWLT; OWLT WS; SBG; SBG WS)
Class: 3/31/2021 - 10/4/2021 and/or were holders of Sandbridge shares entitled to participate in the July 2021 shareholder vote on the merger with Owlet
Lead Plaintiff Motion Deadline: January 18, 2022
SECURITIES FRAUD, MISLEADING PROSPECTUS
To learn more, visit https://claimsfiler.com/cases/nyse-owlt/

Peloton Interactive, Inc. (PTON)
Class Period: 12/9/2020 - 11/4/2021
Lead Plaintiff Motion Deadline: January 18, 2022
SECURITIES FRAUD
To learn more, visit https://claimsfiler.com/cases/nasdaq-pton-1/

Zillow Group, Inc. (Z, ZG)
Class Period: 2/10/2021 - 11/2/2021
Lead Plaintiff Motion Deadline: January 18, 2022
SECURITIES FRAUD
To learn more, visit https://claimsfiler.com/cases/nasdaq-z-1/

If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact us toll-free (844) 367-9658 or visit the case links above.

If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com


News Provided by GlobeNewswire via QuoteMedia

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory DLBCL, PMBCL and FL3B

Recommendation for approval based on results from TRANSCEND NHL 001, the largest pivotal trial of patients with large B-cell lymphoma after at least two prior therapies, and TRANSCEND WORLD

Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after two or more lines of systemic therapy. The CHMP recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU).

Keep reading... Show less
Komo Plant Based Foods Introduces Komo Plant-Based Desserts Line

Komo Plant Based Foods Introduces Komo Plant-Based Desserts Line

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce the launch of new products as part of its plant-based desserts line. This week Komo launched three variations of a vegan and gluten-free cheesecake made with cultured coconut yogurt (from Yoggu Foods) and Cashew with an oat crust, which include a Vanilla Cheezecake, a Mango Cheezecake and a Strawberry Cheezecake

A picture containing text, food, dessertDescription automatically generated

Since September 2021, Komo has been developing the cheezecakes in its research and development test kitchen. Each product developed by Komo uses 100% plant-based and wholesome ingredients to create premium comfort favourites that make plant-based eating easy yet ultimately satisfying.

Keep reading... Show less

Top 5 Life Science ETFs (Updated January 2022)

Taking a position in a life science-focused exchange-traded fund (ETF) provides exposure to biotech and pharma companies while mitigating the risks of holding shares in a single company.

Life science ETFs achieve this diversification by tracking a basket of biotechnology and pharmaceutical stocks in the healthcare sector under one umbrella. ETF managers often narrow down the focus of the ETFs even further to follow a specific aspect of the market, and they typically adjust the weight of its holdings to match movements in the industry and give investors the best possible returns.

There are many options when it comes to life science ETFs, and to help investors understand their options, the Investing News Network has listed the top-performing life science ETFs over the past year.

Keep reading... Show less
BioHarvest Sciences Inc. Projects 2022 Revenue to Grow 2.5X-3.5X to a Range of USD $5M-$7M

BioHarvest Sciences Inc. Projects 2022 Revenue to Grow 2.5X-3.5X to a Range of USD $5M-$7M

  • 2022 Revenue will include sales of VINIA® and Cannabis, both with high gross margins
  • Major investments in the BioFarming platform and Intellectual property
  • New patent application covers a 700% increase in Bioreactor production output

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or "the Company") announces that following the successful over-delivery of revenue targets versus guidance provided in 2021, the Company is estimating 2022 revenue to be between USD $5M-$7M, representing a significant growth of 2.5X-3.5X over 2021. The range in guidance is due to two primary determinants; the speed in which the biological technology transfer to its new 20 Tonyear facility is completed, and regulatory timelines influencing the conversion of the existing 2 Tonsyear facility from VINIA to the production of Cannabis.

The Company is also projecting to achieve break-even cash flow in 2023, when the business reaches its first scaling point. For 2022, BioHarvest plans to continue to invest heavily in R&D (as a percentage of total revenue) and in the building of manufacturing capacity for its Cannabis vertical in Israel and abroad.

Keep reading... Show less

Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine

-- Enrolled Patients in These Studies May Continue Receiving Study Medicine --

-- Studies Outside of Combination with Azacitidine Unaffected --

Keep reading... Show less
Komo Plant Based Foods to be Available for Online Purchase Across the United States through GTFO It's Vegan

Komo Plant Based Foods to be Available for Online Purchase Across the United States through GTFO It's Vegan

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce that it will soon be available for order online throughout the United States through GTFO It's Vegan, a progressive online vegan market serving consumers across the U.S

Komo received a purchase order from GTFO and plans to ship its first pallet of Komo plant-based comfort foods to GTFO headquarters in California this week. Consumers across the United States will soon be able to order, for home delivery, all of Komo's frozen products online at GTFO It's Vegan.

Keep reading... Show less

Latest Press Releases

Related News

×